Ocuphire Pharma to Acquire Opus Genetics
Shots:
- Ocuphire will acquire all the stocks of Opus to form a combined entity, ‘Opus Genetics’, focusing on gene therapies for IRDs
- Acquisition adds AAV-based gene therapies for IRDs, Phentolamine Ophthalmic Solution 0.75% [in P-III (VEGA-3) for presbyopia & (LYNX-2) for dim light vision disturbances post-surgery], APX3330 (to be developed under an alliance for non-proliferative diabetic retinopathy) & OPGx-LCA5 (in P-I/II for LCA5 with 1st pediatric patient enrollment expected in Q1’25 & initial data in Q3’25)
- Cash runway has been extended into 2026 during which data from pediatric patients in OPGx-LCA5’s P-I/II & initial patients in OPGx-BEST1’s P-I/II are expected. The P-III (LYNX-2 & VEGA-3) trials are enrolling actively, with top-line data expected in Q1 & H1’25, respectively
Ref: Ocuphire | Image: Opus
Related News:- Lundbeck to Acquire Longboard Pharmaceuticals, Strengthening its Neuroscience Portfolio
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
